LYNK Pharmaceuticals, established in 2018, is a promising player in the biotechnology and pharmaceutical sectors. With a focus on pioneering novel treatments for oncology, immunology, and inflammatory diseases, the company is based in Hangzhou, Zhejiang, China.
Recently, LYNK Pharmaceuticals secured a significant CNY122.00 million Series C investment on September 21, 2023. This funding round was backed by a robust group of investors, including Lilly Asia Ventures, New Alliance Capital, 杭州海邦投资管理有限公司, Prosperity Investment, Zhongjin Shengshi Investment, Lianxing Capital, Howbuy Primary Fund, and Haomai Fund of Funds.
This investment propels LYNK Pharmaceuticals towards amplifying its research and development efforts, signaling confidence from top-tier investors in its mission to revolutionize therapeutic solutions. As such, it presents a compelling opportunity for stakeholders interested in the health care sector.
